Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2021 Oct 25;31(1):132–141. doi: 10.1158/1055-9965.EPI-21-0677

Figure 2. Alignment of Tumor and Clinical Features by DNA Methylation Clusters in 271 OCCC Tumors.

Figure 2.

Columns represent samples with those on the left indicating (A) Methylation Cluster 1 tumors and those on the right Methylation Cluster 2 tumors, (B) mutation group (see methods), (C) ARID1A/PIK3CA mutations (yes/yes, yes/no, no/yes, no/no, missing), (D) PIK3CA mutation (yes, no, missing), (E) ARID1A mutation (yes, no, missing), (F) TP53 mutation (yes, no, missing), (G) WGD, whole-genome duplication (yes, no, missing), (H) total aneuploidy (none, 1–10, 11–20, 21–29, missing), (I) stage (early, advanced, missing), (J) residual disease (macroscopic, no macroscopic, missing), (K) race (White non-Hispanic, Asian, Black, missing), (L) Illumina Infinium Beadchip (HumanMethylation450, Methylation EPIC), (M) continent (North America, Europe, Australia). Samples are ordered based on hierarchical clustering which used nsNMF two-cluster analysis, although the dendrogram is suppressed.